Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Labcorp reported Q3 2026 revenue of $3.81 billion, up 6.9% year-over-year (5.5% organic), with adjusted EPS of $4.78 up 14.5% and GAAP diluted EPS of $3.22. Free cash flow rose to $412.2 million from $280.5 million, and adjusted operating margin expanded 60 bps to 15.0% on organic growth and efficiency gains. Full-year 2026 guidance was raised: enterprise revenue growth to 5.9%-6.7% and adjusted EPS to $18.30-$18.70, up 18 cents at the midpoint.
Key figures
- Eps
- 3.22
- Revenue
- 3810000000
- Guidance
- FY2026 enterprise revenue $14,779M-$14,887M (growth 5.9%-6.7%); adjusted EPS $18.30-$18.70, raised from $18.10-$18.55; FCF $1,240M-$1,360M
- Revenue Yoy
- 6.9%
- Fcf
- 412200000
- Backlog
- $8.92 billion
- Total debt
- 5850000000
- Adjusted eps
- 4.78
- Organic growth
- 5.5%
- Adjusted eps yoy
- 14.5%
- Operating income
- 402100000
- Ttm book to bill
- 1.1
- Biopharma revenue
- 866700000
- Buyback remaining
- 1400000000
- Dividend per share
- 0.72
- Operating cash flow
- 563800000
- Adjusted operating income
- 570000000
- Adjusted operating margin
- 15.0%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.